Systematic Review: Randomized, Controlled Trials of Nonsurgical Treatments for Urinary Incontinence in Women

Tatyana A. Shamliyan, MD, MS; Robert L. Kane, MD; Jean Wyman, PhD; and Timothy J. Wilt, MD, MPH

**Background:** Urinary incontinence in women is a common problem that adversely affects quality of life.

**Purpose:** To synthesize evidence of management of urinary incontinence in women.

**Data Sources:** MEDLINE, CINAHL, and the Cochrane Library.

**Study Selection:** 96 randomized, controlled trials (RCTs) and 3 systematic reviews published in English from 1990 through May 2007.

**Data Extraction:** Using standardized protocols, reviewers abstracted cases of continence, improvement of urinary incontinence, and prevalence of urinary incontinence to calculate risk difference.

**Data Synthesis:** Compared with regular care, pelvic floor muscle training plus bladder training resolved urinary incontinence (pooled risk difference, 0.13 [95% CI, 0.07 to 0.20]). Pelvic floor muscle training alone resolved or improved urinary incontinence compared with regular care, although the effect size was inconsistent across studies. Different injectable bulking agents and medical devices were associated with similar continence and improvement rates. Electrical stimulation failed to resolve urinary incontinence. Oral hormone administration increased rates of urinary incontinence compared with placebo in most RCTs (1243 women). Transdermal or vaginal estrogen resulted in inconsistent improvement of urinary incontinence. Adrenergic drugs did not resolve or improve urinary incontinence. Oxybutynin or tolterodine resolved urinary incontinence compared with placebo (pooled risk difference, 0.18 [CI, 0.13 to 0.22]). Duloxetine compared with placebo improved (pooled risk difference, 0.11 [CI, 0.07 to 0.14]) but did not resolve urinary incontinence, with no significant dose-response association.

**Limitations:** Inconsistent measurements of outcomes limited the findings. Predictors of better effect have not been identified in RCTs.

**Conclusion:** Moderate levels of evidence suggest that pelvic floor muscle training and bladder training resolved urinary incontinence in women. Anticholinergic drugs resolved urinary incontinence, with similar effects from oxybutynin or tolterodine. Duloxetine improved but did not resolve urinary incontinence. The effects of electrostimulation, medical devices, injectable bulking agents, and local estrogen therapy were inconsistent.


For author affiliations, see end of text.

---

Prevalence estimates of urinary incontinence vary according to the definition and the method of data collection (1–13). In general, urinary incontinence affects about 19% of women age 19 to 44 years, 25% of those age 45 to 64 years, and 30% of those age 65 years and older. About 18% of younger women (19 to 44 years of age) (14) and 28% of women older than age 65 years (15) experience daily urinary incontinence, whereas 30% of women older than age 65 years (8, 16–20) and 27% of middle-aged women (17, 18, 21) report severe urinary incontinence. The severity of incontinence influences quality of life and treatment decisions (22, 23).

Clinical interventions to reduce urinary incontinence (24–34) have been extensively reviewed by the Cochrane Collaboration, the International Consultation on Incontinence (22, 23, 35), and the Agency for Healthcare Research and Quality (36, 37). Most studies examined short-term curative effects of treatment in participants with urinary incontinence. The basis for measuring successful treatment varied across the studies that examined different interventions.

The present review synthesizes evidence on the effectiveness of nonsurgical clinical interventions to treat urinary incontinence in community-dwelling women. This review was commissioned as background material for a National Institutes of Health Office of the Medical Applications of Research State of the Science Conference on Prevention of Fecal and Urinary Incontinence. The full report can be found at www.ahrq.gov/downloads/pub/evidence/pdf/furad/furad.pdf.

See also:

**Print**
- Related article: 449

**Web-Only**
- Appendix Tables
- CME quiz
- Conversion of graphics into slides

---

This article has been corrected. The specific correction appears on the last page of this document.
Methods

Data Sources

We identified studies from MEDLINE (via PubMed), CINAHL, Cochrane databases, and manual searches of reference lists from systematic reviews and the proceedings of the International Continence Society (Appendix Table 1, available at www.annals.org).

Study Selection

Two investigators independently decided on study eligibility according to recommendations from the Cochrane Handbook for Systematic Reviews of Interventions (38) to include original publications of randomized, controlled trials (RCTs) that were published in English from 1990 to May 2007. Full texts of the RCTs that examined the effects of nonsurgical clinical interventions on urinary incontinence in community-dwelling women were eligible for the review. We excluded secondary data analyses, case reports, case series, and RCTs that did not report patient outcomes. We also excluded RCTs that analyzed surrogate outcomes of subjective and objective measures of severity of urinary incontinence, including continuous changes in the number of incontinence episodes or pad use, and urodynamic variables.

We excluded, but further assessed for selection bias, 17 RCTs published before 1990, 2 RCTs conducted in nursing home residents (39, 40), and 2 RCTs that examined long-term indwelling catheters or bed pads (41, 42). One study of eligible medications was analyzed in the Cochrane review (43) and is included in our present analysis (44). Several RCTs examined drugs that were not eligible for our review (45–47). We concluded that we did not omit clinically important, relevant information by restricting our review to articles published from 1990 to May 2007. The information about all outcomes can be found in the full-text report, available at www.ahrq.gov/downloads/pdf/furad/furad.pdf.

Data Extraction and Quality Assessment

Two researchers abstracted the data by using standardized forms that elicited information about study samples, interventions, designs, and outcomes. Study quality was analyzed by using the following criteria: participant selection, length and loss of follow-up, use of intention-to-treat principle, masking of the treatment status, randomization scheme, adequacy of randomization and allocation concealment, and justification of sample sizes (evidence tables can be found at www.ahrq.gov/clinic and in Appendix Tables 2 and 4 to 10, available at www.annals.org) (48). We used the Grading of Recommendations Assessment, Development and Evaluation working group definitions to evaluate the overall strength of the evidence as high, moderate, low, very low, or insufficient (49, 50). The number of events, including prevalence of urinary incontinence, improvement of urinary incontinence, and continence after interventions in the active treatment and control groups, was abstracted to calculate relative risk and risk difference with 95% CIs among randomly assigned women; the intention-to-treat principle was applied (51, 52). The number of events among treatment groups was calculated from the reported rates among randomly assigned or analyzed women for intention-to-treat analysis. Baseline data were compared in the studies to test differences in the target population and unusual patterns in the data (53, 54). Errors in data extractions were assessed by comparing the established ranges for each variable and the data charts with the original articles. Reproducibility of the results was confirmed by repeating the calculations with different models. The analytic framework for the systematic review and meta-analyses was created according to the Quality of Reporting of Meta-Analyses statement (55).

Applicability of the population was estimated by evaluating the inclusion of women in clinical trials (56). Applicability of the intervention duration was high for studies with a follow-up of 1 year or more and was acceptable for studies with a follow-up of 6 to 12 months.

We used several strategies to reduce bias, including a comprehensive literature search of published and unpublished evidence in several databases, a search of reference lists of systematic reviews and proceedings of the International Continence Society, and contacts with experts for additional references.

Data Synthesis and Statistical Analysis

We report clinical definitions of urinary incontinence as they were used by the authors of the original studies and with calculated rates of continence and improvement for purposes of comparison: the number of participants continent after the clinical interventions, the number of participants with improvement in severity of urinary incontinence, and the number of participants with prevalent cases of urinary incontinence. We defined long-term (>6 months’ duration at follow-up) continence as a primary outcome for the present review because continence is the better-defined and most important clinical outcome. In contrast, definitions of urinary incontinence and improvement in urinary incontinence included presence as well as frequency and severity of symptoms. The rates of continence could not always be interpreted as the reciprocal of the rates of incontinence if trials reported only cases of urinary incontinence but excluded cases of improved urinary incontinence. The efficacy of clinical interventions was analyzed from the trials that compared active treatments with placebo, regular care, or no active treatments. The comparative effectiveness of the interventions was analyzed from the trials with active controls, long-term follow-up, adequate sample size, and intention-to-treat analysis (57).

Pooling criteria included RCTs that reported outcomes after the same clinical interventions (58). Meta-analysis was used to assess the consistency of the association between treatments and urinary incontinence outcomes with random-effects models (59). Consistency in results...
was tested by comparing the direction and strength of the association. Chi-square tests and $I^2$ tests were used to assess heterogeneity in study results—a $P$ value less than 0.01 and an $I^2$ value greater than 50% were considered high (60, 61). We conducted meta-regression analyses by using the dose of the drug tested in individual RCTs (62). We could not perform formal meta-analyses for all treatments and outcomes because of methodologic diversity among the trials and different measurements and definitions of the outcomes. The absolute risk difference in rates of outcomes in the active and control groups was calculated for each study and in pooled analysis (63, 64). To permit the studies with zero events in one group to have the correct CIs (65, 66), we used 0.5 zero-cell correction (65) and compared the results of Peto, Mantel–Haenszel, and DerSimonian and Laird random-effects and fixed-effects method summary estimates (65, 66). Calculations were performed by using STATA software (STATA, College Station, Texas) at a 95% CI (63).

Role of the Funding Source
The Agency for Healthcare Research and Quality suggested the initial questions and provided copyright release for this manuscript but did not participate in the literature search, data analysis, or interpretation of the results.

RESULTS
Of 248 RCTs on urinary incontinence interventions, we included 96 that examined nonsurgical treatments in women and reported patient outcomes (Figure 1). The Table shows evidence grades and a summary of the comparative conclusions. The studies included women with mixed urinary incontinence, predominant symptoms of stress urinary incontinence (67–78), urodynamic stress urinary incontinence (79–87), predominant urge urinary incontinence (88), overactive bladder with urge urinary incontinence (89–94), or minimal urinary incontinence (95–97) (Appendix Tables 2 and 4 to 10, available at www.annals.org). The studies did not explicitly exclude women with other types of urinary incontinence; therefore, the effects of the treatments can be applied to women with mixed urinary incontinence.

Urinary continence after various interventions was
defined as self-reported ability to control urination according to voiding diaries and scales, negative results on a pad test, negative stress test results, or a combination of these (Appendix Tables 2 and 4 to 6, available at www.annals.org). The definitions of improvement in urinary incontinence varied across RCTs from perception of self-reported improvement to objective reduction by 50% to 75% in urinary incontinence episodes reported in a voiding diary.

Pelvic Floor Muscle Training Compared with Regular Care

We found moderate evidence from 4 RCTs (n = 229) of stress urinary incontinence (Table) that continence rates (Figure 2) and improvement in urinary incontinence were higher after pelvic floor muscle training, but the effect size was not consistent because of 2 trials with sparse data (98, 99). Neither of the latter 2 RCTs (Appendix Table 2, available at www.annals.org) planned intention-to-treat...
analysis, justified the sample size, or reported no con-
tinence (98) or improvement in urinary incontinence (99)
after regular care. We compared pooled relative risk, risk
difference, and odds ratios of resolved and improved uri-
nary incontinence to seek consistent estimates of statisti-
cally significant overall effects from the same treatments on
different scales (Appendix Table 3, available at www.annals.org). We consider valid only the results that were consistent
across RCTs and showed significant benefit from the treat-
ments according to multiple (relative risk and odds ratio)
and absolute (absolute risk difference) measures. Pooled
relative risk for continence after pelvic floor muscle train-
ing (7.1 [95% CI, 2.8 to 18.4]) (80, 98–100) and pelvic
floor muscle training with biofeedback (11.2 [CI, 2.2 to
56.4]) (98, 100) were significant and consistent across the
studies. Pooled Peto odds ratios, used for RCTs with no
events or small rates of the outcomes, showed consistent
benefits from both treatments for resolved but not im-
proved urinary incontinence (Appendix Table 3, available
at www.annals.org). However, pooled absolute risk dif-
fferences of resolved or improved urinary incontinence were
inconsistent across the studies. Considering that relative
risk and absolute risk difference, but not odds ratios, are
the most appropriate measures of clinically important ef-
fects of the treatments in RCTs (58, 101), available data
did not show that pelvic floor muscle training alone or
with biofeedback provided consistent valid benefit for uri-
nary incontinence.

Only 1 trial (86) examined bladder training in 131
women with urodynamic stress urinary incontinence and
reported higher rates of improvement, but not continence,
compared with regular care (Figure 2). The results of this
RCT may be compromised because the study did not use
intention-to-treat analysis, mask the treatment status, jus-
tify the sample size, or clearly describe allocation conceal-
ment (Appendix Table 2, available at www.annals.org).

Figure 2. Effects of pelvic floor muscle training compared with regular care on resolving or improving urinary incontinence in
community-dwelling women (risk difference from individual randomized, controlled trials).

<table>
<thead>
<tr>
<th>Study (Reference), Sample Size (Outcomes, Follow-up)</th>
<th>Risk Difference (95% CI)</th>
<th>Events in Treatment Group, n/n</th>
<th>Events in Control Group, n/n</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pelvic floor muscle training</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lagro-Janssen et al. (152), 66 (*, 3 mo)</td>
<td>0.85 (0.72 to 0.98)</td>
<td>28/33</td>
<td>0/33</td>
</tr>
<tr>
<td>Aksac et al. (98), 50 (*, 2 mo)</td>
<td>0.05 (–0.26 to 0.36)</td>
<td>5/20</td>
<td>2/10</td>
</tr>
<tr>
<td>Burns et al. (100), 135 (*, 6 mo)</td>
<td>0.48 (0.32 to 0.65)</td>
<td>23/43</td>
<td>2/39</td>
</tr>
<tr>
<td>Aksac et al. (98), 50 (†, 2 mo)</td>
<td>0.75 (0.53 to 0.97)</td>
<td>15/20</td>
<td>0/10</td>
</tr>
<tr>
<td>Bo et al. (159), 122 (†, 6 mo)</td>
<td>0.32 (0.12 to 0.51)</td>
<td>11/29</td>
<td>2/32</td>
</tr>
<tr>
<td>Lagro-Janssen et al. (152), 66 (†, 3 mo)</td>
<td>0.18 (0.03 to 0.33)</td>
<td>7/33</td>
<td>1/33</td>
</tr>
<tr>
<td>Burns et al. (100), 135 (†, 6 mo)</td>
<td>0.14 (0.02 to 0.26)</td>
<td>7/43</td>
<td>1/39</td>
</tr>
</tbody>
</table>

| Pelvic floor muscle and bladder training             |                          |                               |                               |
| McFall et al. (103), 145 (*, 3 mo)                   | 0.23 (0.07 to 0.39)       | 44/72                         | 28/73                         |
| Subak et al. (156), 152 (*, 1.5 mo)                  | 0.35 (0.22 to 0.49)       | 39/78                         | 11/75                         |
| Lagro-Janssen et al. (152), 106 (*, 3 mo)            | 0.71 (0.58 to 0.83)       | 40/54                         | 2/56                          |
| Diokno et al. (96), 359 (*, 12 mo)                   | 0.15 (0.05 to 0.25)       | 92/164                        | 80/195                        |
| Kim (102), 33 (†, 3 mo)                              | 0.26 (–0.03 to 0.54)      | 6/16                          | 2/17                          |
| Diokno et al. (96), 359 (†, 12 mo)                   | 0.09 (–0.01 to 0.19)      | 61/164                        | 55/195                        |
| McFall et al. (103), 145 (†, 3 mo)                   | 0.14 (–0.00 to 0.29)      | 25/72                         | 15/73                         |
| Lagro-Janssen (152), 106 (†, 3 mo)                   | 0.17 (0.06 to 0.28)       | 10/54                         | 1/56                          |

| Pelvic floor muscle training with biofeedback        |                          |                               |                               |
| Goode et al. (107), 70 (*, 2 mo)                      | 0.30 (0.10 to 0.51)       | 27/33                         | 19/37                         |
| Aksac et al. (98), 50 (*, 2 mo)                       | 0.00 (–0.30 to 0.30)      | 4/20                          | 2/10                          |
| Burns et al. (100), 135 (*, 6 mo)                     | 0.55 (0.38 to 0.72)       | 24/40                         | 2/39                          |
| Burns et al. (100), 135 (†, 6 mo)                     | 0.20 (0.06 to 0.34)       | 9/40                          | 1/39                          |

| Bladder training                                     |                          |                               |                               |
| Fantl et al. (86), 131 (*, 1.5 mo)                    | 0.51 (0.36 to 0.66)       | 49/65                         | 16/66                         |
| Fantl et al. (86), 131 (†, 1.5 mo)                    | 0.09 (0.00 to 0.18)       | 8/65                          | 2/66                          |

*Improved urinary incontinence. †Resolved urinary incontinence.
Moderate consistent evidence from 4 RCTs suggested that women with both types of urinary incontinence were continent more often after pelvic floor muscle training and bladder training compared with regular care (Figure 2) (96, 99, 100, 102, 103). Despite baseline differences in age, type of urinary incontinence, methods to measure continence, and quality of the studies (Appendix Table 2, available at www.annals.org), a pooled risk difference of 13% (0.13 [CI, 0.07 to 0.20]) was consistent across the studies (Appendix Table 3, available at www.annals.org). Pelvic floor muscle training and bladder training also improved urinary incontinence (absolute risk difference, 0.36 [CI, 0.10 to 0.61]), but improvement was not consistent across the studies. Pelvic floor muscle training showed consistent benefit for resolving but not improving urinary incontinence, confirming that long-term continence is the most clinically desirable and valid patient outcome.

The trials did not examine the predictors of better responses to pelvic floor muscle training. We compared the results from individual studies to analyze the effectiveness of pelvic floor muscle training depending on population and treatment characteristics (Appendix Table 2, available at www.annals.org). Pelvic floor muscle training in groups with skilled physical therapists increased subjective cure from stress urinary incontinence at 6 months of follow-up (relative risk, 15.4 [CI, 2.2 to 110.3]) (80). Women with stress urinary incontinence experienced objective cure after this treatment 6 times more often than did untreated controls (relative risk, 6.1 [CI, 1.5 to 25.1]) (80). Older women with urodynamically diagnosed stress urinary incontinence reported cure 8 times more often than those in regular care at 6 months of follow-up (relative risk, 8.8 [CI, 1.2 to 66]) (100). Individualized behavioral intervention with pelvic floor muscle training for stress urinary incontinence or bladder training for urge urinary incontinence resulted in continence in 19% of women at 3 months of follow-up, with substantial relative benefit compared with regular care (relative risk, 10.4 [CI, 1.4 to 78.3]) (99). Community-based interventions, including education about self-regulation of continence, bladder training, and pelvic floor muscle training, resulted in continence in 35% of women at 3 months of follow-up compared with 30% of those receiving usual care (103). Some evidence suggested the preventive effects of clinical interventions on urinary incontinence. At 12 months of follow-up, the continence rates after a behavioral modification program (including pelvic floor muscle training and bladder training) implemented in 359 postmenopausal, continent women 55 years of age and older were the same as those in patients receiving usual care (continence rate, 37% vs. 28%) (96, 97) (Appendix Table 2, available at www.annals.org). Intensive lifestyle therapy to maintain loss of at least 7% of initial body weight and to engage in moderate-intensity physical activity reduced stress urinary incontinence by 15% after 2.9 years of follow-up in the Diabetes Prevention Program RCT among 2191 overweight prediabetic women with a mean body mass index of 24 kg/m² or greater (relative risk, 0.85 [CI, 0.73 to 0.99]) (95).

**Comparative Effectiveness of Pelvic Floor Muscle Training**

The results from 19 RCTs of pelvic floor muscle training with biofeedback compared with other treatments (including education, bladder training, medical device, or medications) suggested similar effects on continence and improvement of urinary incontinence in women, without statistically significant relative benefit (Appendix Table 2, available at www.annals.org). A rehabilitation program implemented by nurse continence advisors and consulting urogynecologists, which included bladder training, gradual increase in fluid intake, pelvic floor muscle training, and transvaginal electrical stimulation, resulted in urinary continence in 50% of women at 3 months, but with no statistically significant differences compared with short-term consultation and bladder training (104). Women with urodynamically diagnosed stress urinary incontinence were continent 4 times more often 15 years after intensive pelvic floor muscle training that was supervised by a physical therapist compared with women participating in home exercise (relative risk, 4.02 [CI, 1.54 to 10.53]) (105). Individualized pelvic floor muscle training and bladder training increased continence rates by 158% compared with group exercises in 530 women after 12 months of follow-up (relative risk, 1.58 [CI, 1.05 to 2.36]) (106). Behavioral training (biofeedback-assisted pelvic floor muscle training, bladder control strategies, and self-monitoring with bladder diaries) improved urinary incontinence compared with self-administered behavioral training administered with a self-help booklet (relative risk, 1.42 [CI, 1.1 to 1.8]; risk difference, 0.24 [CI, 0.08 to 0.39]) in 200 women followed for 2 months (1 RCT) (107).

**Physical Rehabilitation Therapies**

Inconsistent low-level evidence from 12 RCTs did not show that magnetic or electrical stimulation cured or improved urinary incontinence in women better than did sham stimulation or pelvic floor muscle training (Appendix Table 4, available at www.annals.org).

Electrical stimulation resulted in continence in about 20% of women (84, 108). However, 2 RCTs that assessed continence at 6 months or more of follow-up failed to show statistically significant benefit from electrical stimulation compared with continence services or medications (80, 108). Other RCTs also did not demonstrate significant relative benefit of electrical simulation compared with Kegel exercises (108), biofeedback-assisted training (79), or placebo (109–112).

The cure rates for urge urinary incontinence after functional magnetic stimulation were more than 70% in 1 RCT (113). The statistically significant relative benefit of active magnetic stimulation over sham stimulation was shown in only 1 trial at 2 months of follow-up (relative
Injectable Bulking Agents

The effects of different bulking agents were examined in 4 RCTs; 1 study included more than 100 women (67), and the other 3 had smaller sample sizes (82, 83, 115). Follow-up lasted 6 (83) to 12 (67, 82, 115) months (Appendix Table 5, available at www.annals.org). Curative effects were shown after intraurethral collagen injection in women with stress urinary incontinence (51.5% were dry during a 24-hour pad test) (67). Transurethral injection of a porcine dermal implant resulted in negative pad test results (cure) in 60% of women with urodynamically proven stress urinary incontinence (83). Transurethral injection of the bulking agent dextran copolymer resulted in objective cure in 15% of women with stress or mixed incontinence (minor and controlled urge component) in whom previous conservative treatments had failed (82).

However, only 1 RCT reported statistically significant relative benefit. This occurred in 63 women with stress urinary incontinence at 12 months of follow-up after transurethral ultrasonography–guided injections of autologous myoblasts and fibroblasts compared with conventional endoscopic injections of collagen (relative risk, 9.5 [CI, 2.53 to 35.63]; risk difference, 0.81 [CI, 0.66 to 0.96]) (115). Other injectable bulking agents did not result in better improvement compared with control treatments.

Medical Devices

Devices studied included a Hodge pessary (81), disposable intravaginal devices (69, 116, 117), urethral plug (118), and vaginal cones (80, 119, 120) (Appendix Table 6, available at www.annals.org). Blocking urinary leakage by inserting a urethral device with a disposable applicator resulted in continence in 67% of women with mixed or stress urinary incontinence but showed no relative benefit compared with a urethral insert with a sterile balloon device (117). A disposable intravaginal device (Conveen Continence Guard, Coloplast, Humlebaek, Denmark) resolved urinary incontinence in 36% of women with stress urinary incontinence compared with 48% of those using a continence tampon (Contrelle Continence Tampon), with no significant difference between treatments (69). One RCT of 122 women with stress urinary incontinence showed no differences in continence rates after use of vaginal cones compared with continence guard services at 6 months of follow-up (80).

Pharmacologic Agents

Hormone Therapy

Oral hormone administration (17 RCTs; n = 1243) resulted in higher rates of urinary incontinence in most studies, with a 50% relative increase in incident mixed urinary incontinence (relative risk, 1.5 [CI, 1.1 to 2.2]) and an 80% increase in incident stress urinary incontinence in postmenopausal women (relative risk, 1.8 [CI, 1.6 to 2.2]) (121) (Appendix Table 7, available at www.annals.org). Incident urge urinary incontinence increased by 30% (relative risk, 1.3 [CI, 1.2 to 1.5]) and total urinary incontinence by 40% (relative risk, 1.4 [CI, 1.3 to 1.6]) after participants received estrogen combined with progesterin (122). Oral estrogen alone without progestin increased incident stress urinary incontinence by 210% (relative risk, 2.1 [CI, 1.7 to 2.5]) (121) and worsened urinary incontinence by 530% (relative risk, 5.3 [CI, 1.2 to 23.5]) (123).

In contrast, transdermal or vaginal administration of estrogen resulted in inconsistent improvement in urinary incontinence in 5 RCTs (n = 710) (116, 124–127). The highest rates of continence were reported after transdermal administration of an estrogen patch (100%) and estrogen gel (90%) among postmenopausal women with self-reported urinary symptoms (126). Topical estrogen in suppositories or creams combined with physiotherapy and electrical stimulation resolved urinary incontinence in 22% of women age 50 to 74 years with regular mild incontinence (>2 leakage episodes per month) compared with 0% in the control group, which did not receive hormone treatment (116).

Other Pharmacologic Agents

We updated 3 systematic Cochrane reviews that reported the effects of drug treatment for urinary incontinence in women. The reviews analyzed randomized trials of anticholinergic drugs for overactive bladder (90), of adrenergic drugs for urinary incontinence (43), and of serotonin and noradrenaline reuptake inhibitors for stress urinary incontinence (70). We estimated the relative risk and risk difference of cure, improvement, or progression from the RCTs published after 1990 (Appendix Tables 8 to 10, available at www.annals.org).

Review of 10 RCTs (71–78, 128, 129) (n = 3633) of duloxetine administered for 3 to 12 weeks in women with predominantly stress urinary incontinence concluded that the drug failed to show better curative effects than placebo (Figure 3 and Appendix Table 8, available at www.annals.org). However, improvement rates and quality-of-life scores were better after duloxetine than after placebo.
The improvement or cure did not demonstrate a dose–response association when 20 to 80 mg of duloxetine were compared (Figure 4). Duloxetine combined with pelvic floor muscle training resulted in higher cure or improvement rates (risk difference, 0.36 [CI, 0.17 to 0.56]) in 1 RCT. Common side effects of duloxetine that were analyzed from the database of 1913 women (130) included

<table>
<thead>
<tr>
<th>Study, Year (Reference)</th>
<th>Duloxetine Dose, mg</th>
<th>Risk Difference (95% CI)</th>
<th>Events in Treatment Group, n/n</th>
<th>Events in Control Group, n/n</th>
</tr>
</thead>
<tbody>
<tr>
<td>Improved (PGI-I)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Norton et al., 2002 (73)</td>
<td>20</td>
<td>0.04 (–0.06 to 0.15)</td>
<td>43/138</td>
<td>37/138</td>
</tr>
<tr>
<td>Norton et al., 2002 (73)</td>
<td>40</td>
<td>0.10 (–0.01 to 0.21)</td>
<td>51/137</td>
<td>37/138</td>
</tr>
<tr>
<td>Cardozo et al., 2004 (74)</td>
<td>80</td>
<td>0.26 (0.11 to 0.40)</td>
<td>17/51</td>
<td>4/52</td>
</tr>
<tr>
<td>Kinchen et al., 2005 (128)</td>
<td>80</td>
<td>0.08 (–0.01 to 0.17)</td>
<td>110/224</td>
<td>93/227</td>
</tr>
<tr>
<td>Millard et al., 2004 (72)</td>
<td>80</td>
<td>0.09 (0.01 to 0.18)</td>
<td>167/227</td>
<td>148/231</td>
</tr>
<tr>
<td>Norton et al., 2002 (73)</td>
<td>80</td>
<td>0.17 (0.06 to 0.29)</td>
<td>62/140</td>
<td>37/138</td>
</tr>
<tr>
<td>Van Kerrebroeck et al., 2004 (75)</td>
<td>80</td>
<td>0.08 (–0.01 to 0.17)</td>
<td>139/247</td>
<td>119/247</td>
</tr>
<tr>
<td>Steers et al., 2007 (129)</td>
<td>120</td>
<td>0.12 (0.01 to 0.23)</td>
<td>81/153</td>
<td>63/153</td>
</tr>
<tr>
<td>Improved (symptoms)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mulcahy et al., 1996 (76)</td>
<td>20</td>
<td>0.28 (0.08 to 0.47)</td>
<td>42/56</td>
<td>18/37</td>
</tr>
<tr>
<td>Zinner et al., 1998 (78)</td>
<td>20</td>
<td>0.32 (0.12 to 0.53)</td>
<td>16/34</td>
<td>5/34</td>
</tr>
<tr>
<td>Zinner et al., 1998 (78)</td>
<td>30</td>
<td>0.47 (0.25 to 0.69)</td>
<td>16/26</td>
<td>5/34</td>
</tr>
<tr>
<td>Zinner et al., 1998 (78)</td>
<td>40</td>
<td>0.31 (0.10 to 0.51)</td>
<td>15/33</td>
<td>5/34</td>
</tr>
<tr>
<td>Cardozo et al., 2004 (74)</td>
<td>80</td>
<td>0.52 (0.35 to 0.68)</td>
<td>30/46</td>
<td>7/52</td>
</tr>
<tr>
<td>Dmochowski et al., 2003 (71)</td>
<td>80</td>
<td>0.18 (0.11 to 0.25)</td>
<td>177/344</td>
<td>114/339</td>
</tr>
<tr>
<td>Millard et al., 2004 (128)</td>
<td>80</td>
<td>0.03 (–0.06 to 0.12)</td>
<td>135/227</td>
<td>131/231</td>
</tr>
<tr>
<td>Van Kerrebroeck et al., 2004 (75)</td>
<td>80</td>
<td>0.18 (0.10 to 0.27)</td>
<td>128/247</td>
<td>83/247</td>
</tr>
<tr>
<td>Cured (objective—CST)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Norton et al., 2002 (73)</td>
<td>20</td>
<td>–0.03 (–0.11 to 0.05)</td>
<td>11/112</td>
<td>15/118</td>
</tr>
<tr>
<td>Norton et al., 2002 (73)</td>
<td>80</td>
<td>0.03 (–0.06 to 0.12)</td>
<td>18/114</td>
<td>15/118</td>
</tr>
<tr>
<td>Cured (objective—diary)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Norton et al., 2002 (73)</td>
<td>20</td>
<td>0.01 (–0.08 to 0.10)</td>
<td>21/128</td>
<td>20/132</td>
</tr>
<tr>
<td>Norton et al., 2002 (73)</td>
<td>40</td>
<td>0.09 (–0.01 to 0.19)</td>
<td>30/123</td>
<td>20/132</td>
</tr>
<tr>
<td>Dmochowski et al., (71)</td>
<td>80</td>
<td>0.05 (0.00 to 0.09)</td>
<td>36/344</td>
<td>20/339</td>
</tr>
<tr>
<td>Millard et al., 2004 (128)</td>
<td>80</td>
<td>0.01 (–0.04 to 0.06)</td>
<td>16/227</td>
<td>14/231</td>
</tr>
<tr>
<td>Norton et al., 2002 (73)</td>
<td>80</td>
<td>0.04 (–0.06 to 0.13)</td>
<td>23/123</td>
<td>20/132</td>
</tr>
<tr>
<td>Ghoniem et al., 2005 (78)</td>
<td>80 + PFMT</td>
<td>0.36 (0.17 to 0.56)</td>
<td>27/44</td>
<td>11/44</td>
</tr>
<tr>
<td>Cured (objective—SPT)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Norton et al., 2002 (73)</td>
<td>20</td>
<td>–0.05 (–0.17 to 0.07)</td>
<td>35/110</td>
<td>42/114</td>
</tr>
<tr>
<td>Norton et al., 2002 (73)</td>
<td>40</td>
<td>0.06 (–0.06 to 0.19)</td>
<td>48/111</td>
<td>42/114</td>
</tr>
<tr>
<td>Norton et al., 2002 (73)</td>
<td>40</td>
<td>0.11 (0.01 to 0.20)</td>
<td>26/112</td>
<td>15/118</td>
</tr>
<tr>
<td>Norton et al., 2002 (73)</td>
<td>80</td>
<td>0.02 (–0.11 to 0.15)</td>
<td>44/113</td>
<td>42/114</td>
</tr>
<tr>
<td>Cured (symptoms)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Norton et al., 2002 (73)</td>
<td>20</td>
<td>0.01 (–0.08 to 0.10)</td>
<td>21/128</td>
<td>20/132</td>
</tr>
<tr>
<td>Norton et al., 2002 (73)</td>
<td>40</td>
<td>0.09 (–0.01 to 0.19)</td>
<td>30/123</td>
<td>20/132</td>
</tr>
<tr>
<td>Dmochowski et al., 2003 (71)</td>
<td>80</td>
<td>0.05 (0.00 to 0.09)</td>
<td>36/344</td>
<td>20/339</td>
</tr>
<tr>
<td>Millard et al., 2004 (128)</td>
<td>80</td>
<td>0.01 (–0.04 to 0.06)</td>
<td>16/227</td>
<td>14/231</td>
</tr>
<tr>
<td>Norton et al., 2002 (73)</td>
<td>80</td>
<td>0.04 (–0.06 to 0.13)</td>
<td>23/123</td>
<td>20/132</td>
</tr>
</tbody>
</table>

CST = cough stress test; PFMT = pelvic floor muscle training; PGI-I = Patient Global Impression of Improvement; SPT = stress pad test.
nausea (23.2%), dry mouth (13.4%), fatigue (12.7%), insomnia (12.6%), constipation (11.0%), headache (9.7%), dizziness (9.5%), somnolence (6.8%), and diarrhea (5.1%). Approximately 20% of women stopped taking duloxetine because of adverse effects.

The Cochrane review of 61 trials of adults with overactive bladder syndrome that compared anticholinergic drugs with placebo or no treatment reported the combined outcome of cure or improvement in urinary incontinence in women and men. We updated the review by analyzing RCTs that included women only (Figure 5; Appendix Table 9, available at www.annals.org). Oxybutynin (immediate-release, 5 to 10 mg) or tolterodine (extended-release, 4 mg) resulted in increased continence rates compared with placebo (pooled risk difference, 0.18 [CI, 0.13 to 0.22]; $I^2 = 0\%$) (91–94, 131). The data were not sufficient for the authors to conclude superiority of oxybutynin or tolterodine. Pooled analysis of 6 RCTs of different drugs resulted in 139% higher rates of cure or improvement in both men and women (relative risk, 1.4 [CI, 1.3 to 1.5]) (90). The authors also reported statistically significant reduction in daily leakage episodes (mean difference, −0.5 episode [CI, −0.7 to −0.4 episode]) after drug administration. The most common adverse effect, dry mouth, was 3 times more common in the medication groups than in the placebo groups (relative risk, 3.00 [CI, 2.70 to 3.34]), with similar rates of withdrawal due to adverse effects (relative risk, 1.11 [CI, 0.91 to 1.36]) (90).

Adrenergic drugs (clenbuterol, norfenefrine, or phenylpropanolamine) did not resolve or improve urinary incontinence compared with placebo or pelvic floor muscle training (76, 91–94, 130–136) (Appendix Table 10, available at www.annals.org).

### Figure 4. Effects of different doses of duloxetine on resolving or improving urinary incontinence in community-dwelling women (risk difference from individual randomized, controlled trials).

<table>
<thead>
<tr>
<th>Duloxetine Dose in Active (Control) Groups</th>
<th>Risk Difference (95% CI)</th>
<th>Events in Treatment Group, n/n</th>
<th>Events in Control Group, n/n</th>
</tr>
</thead>
<tbody>
<tr>
<td>Improved (symptoms)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>30 mg (20 mg)</td>
<td>0.14 (−0.11 to 0.40)</td>
<td>16/26</td>
<td>16/34</td>
</tr>
<tr>
<td>40 mg (20 mg)</td>
<td>−0.02 (−0.25 to 0.22)</td>
<td>15/33</td>
<td>16/34</td>
</tr>
<tr>
<td>40 mg (30 mg)</td>
<td>−0.16 (−0.41 to 0.09)</td>
<td>15/33</td>
<td>16/26</td>
</tr>
<tr>
<td>Improved general health (PGI-I)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>40 mg (20 mg)</td>
<td>0.06 (−0.05 to 0.17)</td>
<td>51/137</td>
<td>43/138</td>
</tr>
<tr>
<td>80 mg (40 mg)</td>
<td>0.07 (−0.04 to 0.19)</td>
<td>62/140</td>
<td>51/137</td>
</tr>
<tr>
<td>80 mg (20 mg)</td>
<td>0.13 (0.02 to 0.24)</td>
<td>62/140</td>
<td>43/138</td>
</tr>
<tr>
<td>Cured (objective—CST)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>40 mg (20 mg)</td>
<td>0.13 (0.04 to 0.23)</td>
<td>26/112</td>
<td>11/112</td>
</tr>
<tr>
<td>80 mg (40 mg)</td>
<td>−0.07 (−0.18 to 0.03)</td>
<td>18/114</td>
<td>28/112</td>
</tr>
<tr>
<td>80 mg (20 mg)</td>
<td>0.06 (−0.03 to 0.15)</td>
<td>18/114</td>
<td>11/112</td>
</tr>
<tr>
<td>Cured (objective—diary)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>40 mg (20 mg)</td>
<td>0.08 (−0.02 to 0.18)</td>
<td>30/123</td>
<td>21/128</td>
</tr>
<tr>
<td>80 mg (40 mg)</td>
<td>−0.06 (−0.16 to 0.05)</td>
<td>23/123</td>
<td>30/123</td>
</tr>
<tr>
<td>80 mg (20 mg)</td>
<td>0.02 (−0.07 to 0.12)</td>
<td>23/123</td>
<td>21/128</td>
</tr>
<tr>
<td>80 mg (PFMT)</td>
<td>0.30 (0.11 to 0.50)</td>
<td>26/46</td>
<td>12/46</td>
</tr>
<tr>
<td>Cured (objective—SPT)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>40 mg (20 mg)</td>
<td>0.11 (−0.01 to 0.24)</td>
<td>48/111</td>
<td>35/110</td>
</tr>
<tr>
<td>80 mg (40 mg)</td>
<td>0.51 (0.41 to 0.62)</td>
<td>107/113</td>
<td>48/111</td>
</tr>
<tr>
<td>80 mg (20 mg)</td>
<td>0.07 (−0.06 to 0.02)</td>
<td>44/113</td>
<td>35/110</td>
</tr>
<tr>
<td>Cured (symptoms)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>40 mg (20 mg)</td>
<td>0.08 (−0.02 to 0.18)</td>
<td>30/123</td>
<td>21/128</td>
</tr>
<tr>
<td>80 mg (40 mg)</td>
<td>−0.06 (−0.16 to 0.05)</td>
<td>23/123</td>
<td>30/123</td>
</tr>
<tr>
<td>80 mg (20 mg)</td>
<td>0.02 (−0.07 to 0.12)</td>
<td>23/123</td>
<td>21/128</td>
</tr>
<tr>
<td>80 mg (20 mg)</td>
<td>0.02 (−0.07 to 0.12)</td>
<td>23/123</td>
<td>21/128</td>
</tr>
</tbody>
</table>

CST = cough stress test; PFMT = pelvic floor muscle training; PGI-I = Patient Global Impression of Improvement; SPT = stress pad test.
NIH Conference | Nonsurgical Treatments for Urinary Incontinence

Figure 5. Effects of anticholinergic drugs on resolving or improving urinary incontinence in community-dwelling women (risk difference from individual randomized, controlled trials).

<table>
<thead>
<tr>
<th>Study, Year (Reference) (Active Treatment)</th>
<th>Risk Difference (95% CI)</th>
<th>Events in Treatment Group, n/n</th>
<th>Events in Control Group, n/n</th>
</tr>
</thead>
<tbody>
<tr>
<td>Placebo</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Burgio et al., 1998 (131) (oxybutynin, 5–10 mg)</td>
<td>0.16 (–0.00 to 0.33)</td>
<td>45/55</td>
<td>34/52</td>
</tr>
<tr>
<td>Dubeau et al., 2005 (91) (tolterodine ER, 4 mg)</td>
<td>0.20 (0.13 to 0.27)</td>
<td>383/569</td>
<td>134/285</td>
</tr>
<tr>
<td>Khullar et al., 2004 (93) (tolterodine ER, 4 mg)</td>
<td>0.15 (0.08 to 0.22)</td>
<td>347/569</td>
<td>131/285</td>
</tr>
<tr>
<td>Tolerodine ER, 4 mg</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Dioikno et al., 2003 (92) (oxybutynin ER, 10 mg)</td>
<td>0.06 (0.01 to 0.12)</td>
<td>90/391</td>
<td>67/399</td>
</tr>
<tr>
<td>Oxybutynin IR, 5 mg</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Anderson et al., 1999 (94) (oxybutynin CR, 5–20 mg)</td>
<td>–0.08 (–0.20 to 0.04)</td>
<td>4/53</td>
<td>8/52</td>
</tr>
</tbody>
</table>

CR = controlled release; ER = extended release; IR = immediate release.

Our review confirms the diversity of interventions used, populations, sampling strategies, definitions, and outcome measurements (22, 137). The quality of most of the RCTs was good; participants were not excluded from the analysis of outcomes, and randomization was adequate. However, allocation concealment was inadequate in a large proportion of RCTs (Appendix Tables 2 and 4 to 10, available at www.annals.org). Variations in populations, interventions, and outcome measures, rather than RCT quality, resulted in heterogeneity between studies.

Studies of behavioral interventions, including pelvic floor muscle training, bladder training, and biofeedback among community-dwelling women, relied largely on convenience samples that involved recruiting participants in clinics (104, 138); few studies reported population-based recruitment (95). Selection criteria varied for the same interventions. For example, only women with intact uteri were included in some (122, 139–141), but not all (123), RCTs of hormone therapy. Baseline characteristics of the participants were balanced, with stratified randomization in few RCTs (125, 142). However, some clinical trials reported statistically significant differences at baseline among treatment groups despite randomization (143, 144). Pooling analysis was questionable because of clinical and methodologic differences across the studies included in the present report and previous systematic reviews (28, 31). Future research is required to determine the predictors of the long-term curative effects of treatments in women from different age and ethnic groups.

Despite extensive efforts to standardize outcome assessment for urinary incontinence (145), the included RCTs measured a variety of outcomes, including self-reported symptoms, signs, and improvement; severity of urinary incontinence as assessed by voiding diaries; pad test weights; and condition-specific quality of life. The measurement of outcomes was inconsistent within and across the studies (Appendix Tables 2 and 4 to 10, available at www.annals.org). Objective improvements in selected physiologic measures were not consistent after the same interventions and did not correlate with self-reported continence and reduction in severity of urinary incontinence. These outcomes were excluded from the present review but are available in the full report (www.ahrq.gov/downloads/pub/evidence/pdf/furad/furad.pdf). The effects on quantitative measures of incontinence, including frequency and amount of leakage as measured by a voiding diary, were smaller than qualitative improvements in symptoms. Other systematic reviews analyzed predominantly self-reported cure and improvement in urinary incontinence and concluded that the data are not sufficient to permit proposing invasive and costly urodynamic testing as a measure of success (33).

The criteria for deeming a treatment successful are not well established. Pooled analyses showed substantial heterogeneity across interventions and reported outcomes. Patients and clinicians need to know comparative effectiveness of available treatments on valid and clinically meaningful outcomes. Long-term continence should be the primary outcome for future clinical trials. Consistently sig-
significant benefits across the studies from available treatments on absolute rates of cured urinary incontinence should be used for clinical decisions to improve the quality of life in community-dwelling women.

Despite substantial heterogeneity among studies, attributable benefit for public health can be estimated from individual RCTs. Intensive lifestyle changes would avoid 54 cases of stress urinary incontinence per 1000 treated women (95). Pelvic floor muscle training would resolve 490 cases of stress urinary incontinence (105), 80 cases of any urinary incontinence (106), and 167 cases of stress or urge urinary incontinence (99) per 1000 treated women. Magnetic stimulation therapy would resolve 390 cases of urge urinary incontinence (113) and the administration of tolterodine (extended-release, 4 mg), 202 cases of urge urinary incontinence (91) per 1000 treated women.

We analyzed the available information on participant characteristics, randomization, and outcomes that were selected for publication. Well-designed RCTs of pharmacologic agents did not report long-term continence. We did not review RCTs of solifenacin, darifenacin, or trospium because they included participants of both sexes with overactive bladder and did not report resolved or improved urinary incontinence in women (Appendix Table 1, available at www.annals.org) (90).

Pelvic floor muscle training combined with bladder training effectively resolved urinary incontinence in women. The long-term effects of combined behavioral and drug therapies on continence rather than surrogate tests need further investigation. Administrative databases can provide useful information on comparative treatment effectiveness, but the results can be biased if provider characteristics are ignored.

The effectiveness of clinical interventions in subgroups of participants by race, comorbid conditions and concomitant treatments, and baseline pelvic floor dysfunction has not yet been well established. Larger trials with recruitment of high-priority populations could yield enough participants among treatment groups to support a subgroup analysis that would provide valid estimations of treatment effects in different populations. The choice of outcomes should reflect participant perception of cure and quality of life rather than provider evaluation and instrumental testing.

From the University of Minnesota School of Public Health, Minnesota Evidence-based Practice Center, University of Minnesota School of Nursing, University of Minnesota Medical School, and Minneapolis Veterans Affairs Center for Chronic Disease Outcomes Research, Minneapolis, Minnesota.

Acknowledgment: The authors thank the librarians, Jim Beattie, MLIS, Judy Stanke, MA, and Delbert Reed, PhD, for their contributions to the literature search; Sue Duval, PhD, for her contribution to the statistical analysis; Marilyn Eells for editing and formatting the report; and Charmaine Bird and Kristina Mucha for assistance with data entry and formatting tables. They also thank Linda Brubaker, MD, Tomas Griebling, MD, Robert Madoff, MD, Richard Nelson, MD, Joseph Ouslander, MD, Neil Resnick, MD, Carolyn Sampselle, PhD, David Thom, MD, PhD, and Joann Townsend, RN, for serving on the Technical Expert Panel; Chadwick Huckabay, MD, for advice and counsel on urinary incontinence management, and Ingrid Nygaard, Mary H. Palmer, PhD, and Debra Saliba, MD, for reviewing the draft of this report and providing helpful recommendations for revisions and clarifications.

Disclaimer: The authors of this report are responsible for its content. Statements in the paper should not be construed as endorsement by the Agency for Healthcare Research and Quality or the U.S. Department of Health and Human Services.

Grant Support: This project was funded under contract no. 290-02-0009 from the Agency for Healthcare Research and Quality, U.S. Department of Health and Human Services. Additional support for Dr. Wilt was provided by RO1-NIDDK-DK 063300-01A2.

Potential Financial Conflicts of Interest: Consultancies: J. Wyman (Eli Lilly, Pfizer).

Requests for Single Reprints: Robert L. Kane, MD, Division of Health Policy and Management, University of Minnesota School of Public Health, D351 Mayo (MMC 197), 420 Delaware Street SE, Minneapolis, MN 55455; e-mail, kanex001@umn.edu.

Current author addresses are available at www.annals.org.

References
12. Burgio KL, Matthews KA, Engel BT. Urinary incontinence and falls in older women: prevalence, incidence, and correlates of
NIH Conference: Nonsurgical Treatments for Urinary Incontinence


Nonsurgical Treatments for Urinary Incontinence


132. Hilton P, Tweddell AL, Mayne C. Oral and intravaginal estrogens alone and in combination with alpha-adrenergic stimulation in genuine stress inconti-

133. Ishiko O, Ushiroyama T, Saiki F, Mitsuhashi Y, Tamura T, Yamamoto K, et al. beta(2)-adrenergic agonists and pelvic floor exercises for female stress inconti-
nence and in combination with alpha-adrenergic stimulation in genuine stress inconti-

menopausal women treated with oral estrogen (estriol) and an alpha-adrenocep-
tor-stimulating agent (phenylpropanolamine): a randomized double-blind placebo-


137. Managing acute and chronic urinary incontinence. AHCPR Urinary Inconti-


141. Kol AL, Burger CW, van de Weijer PH, Voestberg GA, Peters-Muller ER, Kenemans P. Micturition complaints in postmenopausal women treated with continuously combined hormone replacement therapy: a prospective study. Ma-

NIH CONFERENCE


143. Wang AC, Wang YY, Chen MC. Single-blind, randomized trial of pelvic floor muscle training, biofeedback-assisted pelvic floor muscle training, and ele-

144. Elser DM, Wymaen JF, McClish DK, Robinson D, Fand JA, Bump RC. The effect of bladder training, pelvic floor muscle training, or combination train-


146. Borello-France DF, Zyczynski HM, Downey PA, Rause CR, Wister JA. Effect of pelvic-floor muscle exercise position on continence and quality-of-life


148. Alweijne D, Metsemakers JF, Meesters IE, van den Borne B. Effectiveness of pelvic floor muscle exercise therapy supplemented with a health education program to promote long-term adherence among women with urinary inconti-


150. Arvonen T, Fianu-Jonasson A, Tyini-Leinie E. Effectiveness of two conser-


154. Godde PS, Burgio KL, Locher JL, Umlauf MG, Lloyd LK, Roth DL. Urodynamical changes associated with behavioral and drug treatment of urge inconti-

155. Burns PA, Pranikoff K, Nochajski T, Desottell P, Hardwood MK. Treat-

156. Burns PA, Pranikoff K, Nochajski T, Desottell P, Hardwood MK. Treat-


163. Lee PE, Kung RC, Druzd HP. Periurethral autologous fat injection as treatment for female stress urinary incontinence: a randomized double-blind con-

164. Chompoosawpee S, Nuntaispud P, Trivijitsilp P, Sentrakul P, Dusitsin N. The use of two estrogen preparations (a combined contraceptive pill versus conjugated estrogen cream) intravaginally to treat urogenital symptoms in post-

165. Waetjen LE, Brown JS, Modelska K, Blackwell T, Vittinghoff E, Cum-


169. Ahtznan K, Sandal B, Shipberg B, Ulmsten U, Stormby N, Lindskog M. Effect of combined treatment with phenylpropoanosamine and estriol, compared with estriol treatment alone, in postmenopausal women with stress urinary inconti-


173. Warming L, Christoffersen C, Riis BJ, Stakkestad JA, Delmas PD, Chris-


Current Author Addresses: Drs. Shamliyan and Kane: Division of Health Policy and Management, University of Minnesota School of Public Health, D351 Mayo (MMC 197), 420 Delaware Street SE, Minneapolis, MN 55455.

Dr. Wyman: University of Minnesota School of Nursing, Room 6-161 Weaver-Densford Hall, 308 Harvard Street SE, Minneapolis, MN 55455.

Dr. Wilt: Minneapolis Veterans Affairs Center for Chronic Disease Outcomes Research, Veterans Affairs Medical Center (111-0), 1 Veterans Drive, Minneapolis, MN 55417.
CORRECTION: REVIEW OF NONSURGICAL TREATMENTS FOR URINARY INCONTINENCE IN WOMEN

A recent review (1) carried over an error from a Cochrane review (2) about the effects of adrenergic drugs for urinary incontinence. The original trials examined the effects of norfenefrine, not norepinephrine (3, 4), but the Cochrane review replaced the name of the drug norfenefrine with norepinephrine. This has been corrected in the online version.

References